Abundant a proliferation-inducing ligand (APRIL)-producing macrophages contribute to plasma cell accumulation in immunoglobulin G4-related disease.
Adult
Aged
Aged, 80 and over
Cell Proliferation
Female
Humans
Immunoglobulin G
/ immunology
Immunoglobulin G4-Related Disease
/ metabolism
Immunohistochemistry
Kidney
/ metabolism
Macrophages
/ metabolism
Male
Middle Aged
Plasma Cells
/ metabolism
Retrospective Studies
Salivary Gland Calculi
/ immunology
Sjogren's Syndrome
/ immunology
Tumor Necrosis Factor Ligand Superfamily Member 13
/ metabolism
APRIL
IgG4–related disease
macrophages
Journal
Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association
ISSN: 1460-2385
Titre abrégé: Nephrol Dial Transplant
Pays: England
ID NLM: 8706402
Informations de publication
Date de publication:
01 06 2019
01 06 2019
Historique:
received:
31
08
2017
pubmed:
17
10
2018
medline:
15
4
2020
entrez:
17
10
2018
Statut:
ppublish
Résumé
This study aimed to investigate the contribution of a proliferation-inducing ligand (APRIL), a member of the tumor necrosis factor (TNF) superfamily implicated in plasma cell survival, to the development of plasma cell-rich lesions in immunoglobulin G4-related disease (IgG4-RD). We performed immunohistochemical staining for APRIL with Stalk-1 and Aprily-8 antibodies specifically recognizing APRIL-producing cells and secreted APRIL, respectively, in renal and submandibular lesions of IgG4-RD in comparison with those of Sjögren's syndrome and sialolithiasis. Numerous Stalk-1-positive APRIL-producing cells were detectable in lesions of IgG4-RD. These cells, identified as CD163-positive M2 macrophages, secreted APRIL that distributed close to and even on infiltrating plasma cells. In contrast, APRIL-producing cells and the secreted form of APRIL were rarely detectable in lesions of Sjögren's syndrome or sialolithiasis. Notably, APRIL expression decreased concomitantly with the level of plasma cell infiltration after successful glucocorticoid treatment. Abundant infiltration into tissue lesions of APRIL-producing M2 macrophages and retention of secreted APRIL in plasma-cell-rich areas support a role for APRIL in the pathogenesis of plasma cell-rich lesions in IgG4-RD.
Sections du résumé
BACKGROUND
This study aimed to investigate the contribution of a proliferation-inducing ligand (APRIL), a member of the tumor necrosis factor (TNF) superfamily implicated in plasma cell survival, to the development of plasma cell-rich lesions in immunoglobulin G4-related disease (IgG4-RD).
METHODS
We performed immunohistochemical staining for APRIL with Stalk-1 and Aprily-8 antibodies specifically recognizing APRIL-producing cells and secreted APRIL, respectively, in renal and submandibular lesions of IgG4-RD in comparison with those of Sjögren's syndrome and sialolithiasis.
RESULTS
Numerous Stalk-1-positive APRIL-producing cells were detectable in lesions of IgG4-RD. These cells, identified as CD163-positive M2 macrophages, secreted APRIL that distributed close to and even on infiltrating plasma cells. In contrast, APRIL-producing cells and the secreted form of APRIL were rarely detectable in lesions of Sjögren's syndrome or sialolithiasis. Notably, APRIL expression decreased concomitantly with the level of plasma cell infiltration after successful glucocorticoid treatment.
CONCLUSIONS
Abundant infiltration into tissue lesions of APRIL-producing M2 macrophages and retention of secreted APRIL in plasma-cell-rich areas support a role for APRIL in the pathogenesis of plasma cell-rich lesions in IgG4-RD.
Identifiants
pubmed: 30325430
pii: 5133036
doi: 10.1093/ndt/gfy296
pmc: PMC6545467
doi:
Substances chimiques
Immunoglobulin G
0
TNFSF13 protein, human
0
Tumor Necrosis Factor Ligand Superfamily Member 13
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
960-969Informations de copyright
© The Author(s) 2018. Published by Oxford University Press on behalf of ERA-EDTA.
Références
J Allergy Clin Immunol. 2016 Sep;138(3):825-838
pubmed: 26971690
Pancreas. 2011 Oct;40(7):1120-30
pubmed: 21926547
J Exp Med. 1992 Jul 1;176(1):287-92
pubmed: 1613462
Am J Surg Pathol. 2005 Jun;29(6):783-91
pubmed: 15897744
Cell Death Differ. 2005 Jun;12(6):637-48
pubmed: 15846369
Ann Rheum Dis. 2017 Feb;76(2):377-385
pubmed: 27358392
Sci Rep. 2015 Jan 09;5:7696
pubmed: 25571893
Mod Pathol. 2014 Aug;27(8):1126-36
pubmed: 24390219
J Am Soc Nephrol. 2011 Jul;22(7):1343-52
pubmed: 21719792
Cytokine Growth Factor Rev. 2013 Jun;24(3):203-15
pubmed: 23684423
J Immunol. 2007 Dec 1;179(11):7276-86
pubmed: 18025170
Nat Immunol. 2002 Sep;3(9):822-9
pubmed: 12154359
Gut. 2016 Aug;65(8):1322-32
pubmed: 26964842
Arthritis Res Ther. 2016 Nov 25;18(1):273
pubmed: 27884179
J Exp Med. 2005 May 2;201(9):1375-83
pubmed: 15851487
Int Immunol. 2007 Jul;19(7):837-46
pubmed: 17606982
Kidney Int. 2010 Nov;78(10):1016-23
pubmed: 20720530
Immunity. 2014 Apr 17;40(4):582-93
pubmed: 24745334
Blood. 2008 Mar 1;111(5):2755-64
pubmed: 18180376
Rheumatology (Oxford). 2011 Jul;50(7):1211-5
pubmed: 21325391
J Allergy Clin Immunol. 2014 Sep;134(3):679-87
pubmed: 24815737
Blood. 1995 Jan 15;85(2):487-94
pubmed: 7812003
Ann Rheum Dis. 2015 Dec;74(12):2236-43
pubmed: 25143523
Eur J Immunol. 1998 Feb;28(2):508-15
pubmed: 9521060
Blood. 2007 Jan 1;109(1):331-8
pubmed: 17190854
Mod Pathol. 2012 Sep;25(9):1181-92
pubmed: 22596100
Mod Rheumatol. 2012 Feb;22(1):1-14
pubmed: 21881964
Arthritis Res Ther. 2009;11(5):R144
pubmed: 19788740
Blood. 2011 Aug 18;118(7):1838-44
pubmed: 21642598
Arthritis Res Ther. 2016 Jul 13;18:167
pubmed: 27411315
Clin Nephrol. 2013 Mar;79(3):246-52
pubmed: 22841022
Nat Immunol. 2000 Sep;1(3):252-6
pubmed: 10973284
Br J Haematol. 1996 Aug;94(2):318-23
pubmed: 8759892
Clin Immunol. 2015 Jan;156(1):9-18
pubmed: 25450336
Ann Rheum Dis. 2015 Jun;74(6):1171-7
pubmed: 25667206
J Rheumatol. 2010 Jul;37(7):1380-5
pubmed: 20436071
Nat Immunol. 2011 Dec 25;13(2):170-80
pubmed: 22197976
Kidney Int. 2013 Oct;84(4):826-33
pubmed: 23698232
EMBO Rep. 2001 Oct;2(10):945-51
pubmed: 11571266
Mod Rheumatol. 2012 Feb;22(1):21-30
pubmed: 22218969
Arthritis Res Ther. 2012 Apr 24;14(2):R86
pubmed: 22531553
Intern Med. 2011;50(11):1239-44
pubmed: 21628942
J Immunol. 2004 Nov 1;173(9):5361-71
pubmed: 15494482
Immunity. 2007 Jun;26(6):812-26
pubmed: 17570691
Mod Rheumatol. 2012 Nov;22(6):859-70
pubmed: 22262474
Clin Exp Nephrol. 2011 Oct;15(5):615-626
pubmed: 21898030
J Immunol. 2008 Mar 15;180(6):3655-9
pubmed: 18322170
J Gastroenterol. 2015 Apr;50(4):435-44
pubmed: 25005350
Nat Immunol. 2011 Feb;12(2):151-9
pubmed: 21217761
J Clin Invest. 2008 Aug;118(8):2887-95
pubmed: 18618015
N Engl J Med. 2012 Feb 9;366(6):539-51
pubmed: 22316447
Hepatology. 2007 Jun;45(6):1538-46
pubmed: 17518371
Rheumatology (Oxford). 2005 Feb;44(2):227-34
pubmed: 15509627